This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre Leon Berard, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale. Active years: 2026.
Company Filing History:
1 out of 39 
1 out of 123 
1 out of 12 Years Active: 2026
Title: Emmanuel Delay: Innovator in Cancer Prognosis
Introduction
Emmanuel Delay is a notable inventor based in Lyons, France. He has made significant contributions to the field of cancer prognosis through his innovative methods. His work focuses on improving patient outcomes and understanding chemotherapy resistance.
Latest Patents
Emmanuel Delay holds a patent for a prognosis method of cancer. This method involves determining the amount of the product of each of at least 21 genes from a group of 160 genes, as set forth in SEQ ID NO: 1 to SEQ ID NO: 160. This innovative approach aims to provide insights into patient outcomes and the effectiveness of chemotherapy treatments.
Career Highlights
Throughout his career, Emmanuel Delay has worked with prestigious organizations, including the Centre National de la Recherche Scientifique and the Centre Léon Bérard. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Emmanuel Delay has collaborated with notable colleagues, including Véronique Maguer-Satta and Boris Guyot. These partnerships have enriched his research and expanded the impact of his work in cancer prognosis.
Conclusion
Emmanuel Delay's innovative methods in cancer prognosis demonstrate his commitment to improving patient care and treatment outcomes. His contributions to the field are invaluable and highlight the importance of research in advancing medical science.